New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
09:00 EDTSNSSSunesis rises 7.5%
Sunesis is up 7.5%, or 30c, to $4.300
News For SNSS From The Last 14 Days
Check below for free stories on SNSS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
13:30 EDTSNSSSunesis vosaroxin shown to be effective, says Wedbush
Wedbush believes that initial data from a Phase Ib/II study indicates that Sunesis' vosaroxin and decitabine are more effective in treating acute myeloid leukemia and myelodysplastic syndrome than decitabine alone. The firm notes that vosaroxin combined with decitabine appeared to be safe. It reiterates a $10 price target and Outperform rating on Sunesis.
13:00 EDTSNSSSunesis price target raised to $15 from $12 at Roth Capital
Roth Capital raised Buy rated Sunesis' price target to $15 from $12 based on positive Phase I/II combination data with vosaroxin in older front line AML patients announced at AACR.
08:11 EDTSNSSSunesis announces presentation of positive results from Vosaroxin trial
Subscribe for More Information
April 7, 2014
07:27 EDTSNSSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use